Kornimate/medical-research-clean huggingface dataset:
validation of ipswich touch test for diabetic peripheral neuropathy screening in primary care

Conditions: Diabetic Foot

Summary: the goal of this observational study is to assess the accuracy of screening for diabetic peripheral neuropathy by comparing the ipswich touch test with the 10-g monofilament test in patients diagnosed with type 2 diabetes. the main question it aims to answer is: how does the accuracy of the ipswich touch test for identifying peripheral neuropathy compare to the traditional 10-g monofilament test? participants underwent both the ipswich touch test and the 10-g monofilament test.

background: diabetic foot, a severe complication of diabetes, significantly impairs the quality of life of affected individuals. however, it can be prevented through screening for loss of protective sensation in the foot. currently, standard screening methods still require specialized equipment and trained medical professionals. objectives: the aim of this study is to assess the accuracy of screening for diabetic peripheral neuropathy by comparing the ipswich touch test with the 10-g monofilament test in patients diagnosed with type 2 diabetes. methods: this diagnostic study with a cross-sectional design focused on a group of 274 patients with type 2 diabetes who were receiving services at nong khantee subdistrict health promoting hospital in phra phutthabat district, saraburi province. participants underwent both the ipswich touch test and the 10-g monofilament test. statistical analysis included evaluating sensitivity, specificity, negative predictive value, positive predictive value, negative likelihood ratio, positive likelihood ratio, and cohen's kappa statistic to assess the diagnostic reliability of the ipswich touch test.

Eligibility criteria:
inclusion criteria: * being 18 years old or older, having type 2 diabetes * being able to communicate in thai by speaking and listening. exclusion criteria: * aids * alcoholism * any cancer * cerebrovascular disease * chronic foot ulcers, or having foot or toe amputation. * chronic kidney disease stage 4 and 5 * cirrhosis * malnutrition * neurological disease * thyroid hormone deficiency

Keywords: diabetes mellitus ipswich touch test accuracy sensitivity
timing of delivery in fetal growth restriction of uncomplicated women

Conditions: Fetal Growth Restriction

Summary: the goal of the study is to determine whether labor induction at 37 weeks of pregnancy can improve the baby's health at birth when compared with delivery at a later point in the pregnancy.


Eligibility criteria:
inclusion criteria: * singleton pregnancy * gestational age 34 weeks 0 days to 37 weeks 0 days at time of enrollment * dating of pregnancy by last menstrual period consistent with an ultrasound, ultrasound \<21 weeks and 6 days of gestation, or known date of conception in the setting of in vitro fertilization * no known major anomalies (anomalies requiring surgery antenatally or in the neonatal period, anomalies not compatible with life as determined by the physician) * fgr defined as estimated fetal weight (efw) \< 10th percentile by hadlock formula with normal umbilical artery doppler studies and normal amniotic fluid exclusion criteria: * known major fetal anomalies * multiple gestation or selective reduction of multiple gestation after 14 weeks * previous stillbirth at term * indications for delivery at \<39 weeks. common examples include: * placenta previa * placenta accreta * vasa previa * history of classical cesarean section or myomectomy * human immunodeficiency virus (hiv) * oligohydramnios (low amniotic fluid, defined as maximum vertical pocket \<2.0cm) * high-risk pregnancy as determined by the physician. common examples include: * pre-gestational diabetes or gestational diabetes on medication * chronic hypertension on medication * maternal cardiac disease * asthma requiring oral steroids during pregnancy * chronic renal disease * antiphospholipid syndrome * hyperthyroidism * prior stillbirth * systemic lupus erythematous * hemoglobinopathies such as sickle cell disease
comparative efficacy of water & indigo carmine vs. water or air method on adenoma detection rate (adr) - a randomized controlled trial (rct)

Conditions: Colorectal Neoplasms

Summary: adenoma detection rate (adr) is a quality indicator of colonoscopy performed for colorectal cancer screening. population studies have shown that traditional air colonoscopy fails to eliminate post screening colonoscopy cancers or cancer mortality in the proximal colon. the investigators aim to establish the superior effectiveness of combining chromoendoscopy with the water exchange method in detecting more proximal diminutive adenomas during screening colonoscopy in sedated veterans. an improved adenoma detection rate associated with optical colonoscopy will minimize the risk of missed lesions. the improvement may translate into a remedy for the limitations of screening colonoscopy in the proximal colon, e.g. a higher adenoma detection rate may minimize the burden of post screening colonoscopy interval colorectal cancers among the veteran population.

1. design: prospective, single center, patient blinded, randomized controlled trial 2. methods: colonoscopy with traditional air insufflation, water exchange or water exchange plus indigocarmine to aid insertion of colonoscope; split dose bowel preparation; all patients will receive sedation; assessment of serum electrolytes level before and after colonoscopy 1. control method: traditional air insufflation method. 2. study methods: * water exchange method. * water method combined with chromoendoscopy (0.008% indigo carmine). 3. population to be studied veterans between age 50 and 75 referred for first time screening colonoscopy 4. unit(s) of analysis 1. primary outcome: overall adenoma detection rate. 2. secondary outcomes: patient demographic variable and procedure related measures. 5. sampling strategy: all veterans referred for screening colonoscopy will be offered enrollment in the study. 1. sample size calculation. a total of 480 subjects will be recruited and randomized with 160 in each group. 5. subject recruitment: patients referred for screening colonoscopy come from three sources. 6. description of base population and groups to be studied and method of randomization. veterans between age 50 and 75 referred for first time screening colonoscopy. after informed consent, assignment to control or study arm based on computer generated random number codes stored in pre-arranged opaque envelopes.

Eligibility criteria:
inclusion criteria: * asymptomatic veterans scheduled for first time screening colonoscopy and agree to be randomized will be enrolled. exclusion criteria: * patients who decline to be randomized, non screening cases.

Keywords: adenoma detection screening colonoscopy water exchange method chromoendoscopy
institut paoli calmettes multiple myeloma database

Conditions: Multiple Myeloma

Summary: database of institut paoli-calmettes patients diagnosed with multiple myeloma


Eligibility criteria:
inclusion criteria: * multiple myeloma diagnosis exclusion criteria: * diagnosis before 1st january 2008
primary lymphedema and mutation celsr1 (cadherin egf lag seven-pass g-type receptor 1)

Conditions: Primary Lymphedema

Summary: the investigators will describe the expression of mutation celsr1 with codon stop and amino acids substitution mechanism in primary lymphedema, in both clinical examination and imaging exploration

according to the literature, it seems that the mutation of the celsr1 gene is associated with primary lymphedema. thus, the investigators have identified families with celsr1 mutation with codon stop or animo acid substitution mechanisms among patients followed up in vascular medicine department, at montpellier university hospital for primary lymphedema of lower limbs. among the mutation carriers, the investigators have collected the clinical examinations and imaging exploration results, realized systematically during the follow up of all the patient with primary lymphedema (venous doppler, mri of the lymphatic system, lymphoscintigraphy of the lower limbs, abdominal ultrasound), in order to search for a morphological and functional pattern associated with the mutation.

Eligibility criteria:
inclusion criteria: * patient followed up in vascular medicine departement at montpellier university hospital for primary lymphedema of lower limbs, who carries the celsr1 mutation with codon stop or amino acids substitution mechanism. * relatives to the index case who carry the mutation for the segregation study. exclusion criteria: * patients who carry another mutation than celsr1 responsible for primary lymphedema * syndromic form of primary lymphedema * patient not followed up at montpellier university hospital.

Keywords: celsr1 primary lymphedema of lower limbs lymphedema
pins stimulator system for patients with treatment resistant depression

Conditions: Treatment-Resistant Depression

Summary: evaluate the effects and safety of deep brain stimulation (dbs) to treat on patients with treatment-resistant depression (trd) and using functional magnetic resonance imaging (fmri)to evaluate the influence of acupuncture on patients, which will be afford objective evidence for the mechanism of acupuncture on depression.


Eligibility criteria:
inclusion criteria: 1. subject is aged ages 20-70 years 2. diagnosed with non-psychotic major depressive disorder, single or recurrent episode by dsm-iv-tr criteria 3. first episode onset before age 45 4. current episode \> 12 months duration 5. in the current episode: documented resistance (i.e. persistence of the major depressive episode) to a minimum of 4 adequate depression treatments from at least 3 different treatment categories (e.g. ssri's) 6. snri's, tca's, mao-inhibitors, mirtazipine, nefazodone, trazodone, bupropion, lithium augmentation, thyroid augmentation, ect); adequacy of treatments as defined by a score of at least 3 according to the amended antidepressant treatment history form (athf) criteria 7. hamilton depression rating scale (hdrs) of \> 20 at 3 separate baseline visits, rated by 2 separate psychiatrists, baseline 2 and baseline 3 hdrs scores cannot improve ≥ 25% exclusion criteria: 1. patients with hearing impairment 2. failures of important organs and in severe conditions 3. be reluctant or disabled to receive neuropsychological assessments; 4. participate in other clinical trial 5. has a life expectancy of \< 1 year 6. the investigator and/or enrollment review committee, would preclude participation in the study
search for optimal anaesthesia in retrograde intrarenal surgery

Conditions: Kidney Stone

Summary: patients undergoing retrograde intrarenal surgery for kidney stones from november 2017 to may 2018 were prospectively recruited to participate in the study. in each case after the beginning of general anesthesia with mechanical ventilation surgeons were asked to assess the mobility of the operative field and conditions for laser lithotripsy according to the developed questionnaire scale. the questionnaire consisted of 5 degrees of assessment of kidney mobility and each question was scored from 1 to 5, 1 being very mobile (extremely poor conditions for dusting) and 5 completely immobile (ideal conditions for dusting). after this assessment modified technique of general anesthesia was applied called combined respiratory support which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high frequency jet ventilation through endotracheal tube with a respiratory cycle frequency of 300 per minute and maintained during retrograde intrarenal surgery. at the beginning of combined respiratory approach, surgeons were once again asked to assess the mobility of the operative field and the conditions for laser lithotripsy. main ventilation parameters were recorded and compared in both regimens.


Eligibility criteria:
inclusion criteria: * kidneys stones with indications for retrograde intrarenal surgery exclusion criteria: * patients with asa class of greater than 3 * patients with active urinary tract infection were excluded from the study
assessing the feasibility of integrating ear acupuncture into the aeromedical evacuation system from rab to aafb

Conditions: Musculoskeletal Pain

Summary: the purpose of this study is twofold: 1) to test the feasibility of integrating a simple bilateral ear acupuncture procedure (auricular stimulation procedure - asp) into the standard care delivered in the aeromedical evacuation system and 2) to observe and document any changes in pain scores and in-flight related symptoms and factors (e.g. sinus block/pain, ear block pain, nausea/air sickness) typically monitored during transportation of wounded warriors from ramstein air base (rab) to andrews air force base (aafb).


Eligibility criteria:
inclusion criteria: * age 18 or over * nrs pain rating \> 0 * military beneficiaries undergoing aeromedical evacuation from rab to aafb exclusion criteria: * medically unstable or otherwise unable to participate including those with the inability to consent * allergy to metals * ear trauma * sepsis * unhealed wounds on the ears * piercing or scar tissue in any of the ear acupuncture point areas * pregnancy

Keywords: pain acupuncture
efficacy of moxibustion therapy with or without smoke for knee osteoarthritis

Conditions: Pain

Summary: this is a multicentre, randomised, single blinded, parallel-group design clinical trial to assess the effect of moxa smoke in the treatment using moxibustion for knee osteoarthritis.

aim: to assess the effect of moxa smoke in the treatment using moxibustion for knee osteoarthritis. design: this is a multicentre, randomised, single blinded, parallel-group design clinical trial. 138 eligible participants will be randomly allocated into 2 groups (moxibustion group or smoke-free moxibustion group) with a 1:1 allocation ratio, and receive 12 sessions of moxibustion treatment over a period of 4 weeks, three sessions per week. each session will last 30 minutes. the whole study period is 13 weeks, with a 1 week run in period, 4 week treatment phase, and 8 week follow-up phase.the participants will receive moxibustion treatment at three acupoints (ex-le04,st35,st36). in moxa-free smoke moxibustion group, investigators place a purification device(shenzhen conyson electronic technology co, ltd,c200 moxa smoke purification device,shenzhen,china) at the top of the moxibustion to remove the moxa smoke. the primary measurement outcomes are the mean change in the global scale value of the western ontario and mcmaster universities osteoarthritis index(womac) pain and function scores from baseline to 4 weeks. the secondary outcomes are the visual analogue scale (vas) and the patient global assessment. investigators will assess participants at the second visit (before starting moxibustion treatment) and at the 2, 4, 8, and 12 week respectively after the baseline.

Eligibility criteria:
inclusion criteria: participants meeting the following criteria will be included: 1. aged between 40 and 75 years 2. diagnosed with knee osteoarthritis formulated by the american college of rheumatology (acr). 3. the average severity of knee pain not more than 7 points on a visual analogue scale for most days during the past month 4. agree not have the paregoric during the whole treatment phase 5. willingness to participate in a randomized study and to sign the informed consent form. exclusion criteria: participants will be excluded if they have these experiences: 1. inflammatory diseases, including rheumatoid arthritis, cancer, traumatic injury that might be related to the current knee pai 2. autoimmune disease, uncontrolled hypertension 3. diabetes mellitus requiring insulin injection 4. life-threatening cardiovascular or neurological events within the past year 5. chronic respiratory disease,a haemorrhagic disorder 6. alcohol or drug addiction 7. an active infectious disease including tuberculosis 8. a significant knee joint deformity 9. knee replacement surgery for the affected knee 10. knee arthroscopy within the past year 11. steroid injection in the knee joints within the past 3 months 12. injections in the knee joints or joint fluid injection within the past 6 months 13. accept acupuncture, moxibustion, cupping, or herbal medicine within the past 4 weeks

Keywords: moxa smoke moxibustion knee osteoarthritis
cartilage tympanoplasty for recurrent perforation full thickness versus partial thickness graft

Conditions: Cartilage Tympanoplasty

Summary: cartilage tympanoplasty for recurrent perforation full thickness versus partial thickness graft.

to compare between outcomes of full thickness versus partial thickness graft in cartilage tympanoplasty using cartilage slicer

Eligibility criteria:
inclusion criteria: 1 -patients with safe chronic suppurative otitis media 2- patients with recurrent perforations 3- patients with conductive hearing loss- 4- patients above 18 years exclusion criteria: 1. active infection 2. sensorineural hearing loss 3. compromised immune system 4 - patients age below 18 years
pilot study: anti-inflammatory effect of peroperative stimulation of the vagus nerve

Conditions: Postoperative Ileus

Summary: hypothesis: electrical stimulation of the abdominal vagus nerve has an anti-inflammatory effect and represents a new therapeutic approach to shorten postoperative ileus. aims: in the present pilot study, the investigators want to evaluate the anti-inflammatory effect of peroperative electrical stimulation of the vagus nerve. to this end, the following aims are formulated: 1. to optimize the technique of intra-operative electrical vagus nerve stimulation 2. to show that electrical stimulation of the intra-abdominal vagus nerve reduces the inflammatory response to abdominal surgery 3. to evaluate whether electrical stimulation of the vagus nerve leads to clinical improvement (collect pilot data)


Eligibility criteria:
inclusion criteria: * patients with rectal carcinoma eligible for open rectal resection * age between 18 and 70 years exclusion criteria: * preoperative therapeutic abdominal radiation * evident intra-abdominal inflammation (diagnosed by imaging and/or laboratory test results, including abscess or cholecystitis) * american society of anesthesiologists physical-health status classification (asa-ps) \>3 * poorly regulated diabetes (\>200 mg/dl (=11mmol/l))
ulcerative colitis - vedolizumab- with/without prior exposure to anti-tnf（tumor necrosis factor）therapy

Conditions: Ulcerative Colitis

Summary: a case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-tnf therapy in patients with ulcerative colitis starting vedolizumab therapy

inflammatory bowel disease (ibd)- ulcerative colitis (uc) and crohn's disease (cd)- are chronic conditions of the gastrointestinal tract. treatment generally consists of immunosuppression to modify the dysregulated immune responses. vedolizumab, an inhibitor of α4β7, is a highly effective therapy for treating ibd, that minimized adverse effects through its gut selective inhibition of lymphocyte trafficking. however, the mechanism of action remains incompletely characterized especially in those previously treated to other biologics and why some patients are either vedolizumab non-responders or fail to respond over time. we would like to address the question whether anti-tnf non-responders as well as those that either do not respond or fail overtime to respond to vedolizumab identifies a specific population with difficult to treat disease that have alternate trafficking patterns and whether prior exposure to anti-tnf alters the mucosal immune responses, and/or trafficking patterns when compared to anti-tnf naive patients that may help explain impaired response to vedolizumab induction therapy.

Eligibility criteria:
inclusion criteria: * adult patients (\>18 years old) * clinical diagnosis of inflammatory bowel disease (ulcerative colitis) * clinical indication for biologic therapy * naive or failed anti-tnf therapy previously exclusion criteria: * patients allergic or intolerant to vedolizumab, * past use of vedolizumab; * patient unable to give consent to enter the study
safety study of aqueous suppression after ahmed glaucoma valve (agv) implantation

Conditions: Hypertensive Phase

Summary: the agv implant is designed to open when the iop is between 8 mmhg and 10 mmhg, and thus maintains an iop of 8 mmhg or higher. in the early period after glaucoma drainage device (gdd) surgery the intraocular pressure (iop) classically goes through 2 phases. the hypotensive phase occurs immediately after surgery, lasts around 1 week. this is followed by the hypertensive period where the iop tends to rise steadily above 21mmhg. the hypertensive response seems to occur more commonly after ahmed gdd surgery than nonvalved implants, it was reported to occur in 40% to 80% of cases. although the hypertensive phase can last as long as 6 months it is usually during the first 1 to 4 weeks, when there is intense congestion of the bleb wall, that iop is highest. previous study showed that when aqueous comes into contact with conjunctiva and tenon's capsule,an inflammatory reaction occurs.factors such as prostaglandins, eicosanoids, tissue growth factor beta (tgf β)has been shown to occur in glaucomatous aqueous. these mediators induce an inflammatory reaction, and if excessive, will result in fibrosis and poor functioning of the bleb. high pressure within the bleb also results in the secretion of tgf β by the bleb lining. it may result in inflammation of the bleb wall and subsequent fibrosis and poor bleb function. the investigators supposed that with early use of aqueous suppressant medication after agv implantation, the concentration of inflammatory mediators decreased in subconjunctival space and may lead to better iop control after shunt surgery.


Eligibility criteria:
inclusion criteria: * patients with uncontrolled glaucoma requiring agv device implantation. exclusion criteria: 1. history of agv implantation 2. allergy to anti glaucoma medication 3. unable to come for follow up 4. known contraindication to beta blacker such as asthma- chronic obstructive pulmonary disease (copd). heart failure heart block 5. learning difficulty- mental illness or severely ill

Keywords: hypertensive phase success rate agv